Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA5 | O75582 | 14/20 | 0.64 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.53 |
| ▸ | RPS6KB1 | P23443 | 4/20 | 0.52 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.52 |
| ▸ | CDK2 | P24941 | 1/20 | 0.52 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.52 |
| ▸ | GSK3B | P49841 | 2/20 | 0.47 |
| ▸ | PRKACA | P17612 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4761651 | 0.86 | RPS6KA5 (0.67) | RPS6KA5DYRK1ARPS6KB1ROCK1CDK2 | |
| SCHEMBL4716496 | 0.86 | RPS6KA5 (0.62) | RPS6KA5DYRK1ARPS6KB1ROCK1CDK2 | |
| SCHEMBL4761693 | 0.82 | RPS6KA5 (0.69) | RPS6KA5DYRK1ARPS6KB1ROCK1CDK2 | |
| SCHEMBL5469062 | 0.82 | RPS6KA5 (0.72) | RPS6KA5DYRK1ARPS6KB1ROCK1CDK2 | |
| SCHEMBL4717333 | 0.81 | RPS6KA5 (0.61) | RPS6KA5DYRK1ARPS6KB1ROCK1CDK2 | |
| SCHEMBL4716326 | 0.81 | RPS6KA5 (0.78) | RPS6KA5DYRK1ARPS6KB1ROCK1CDK2 | |
| SCHEMBL4718298 | 0.81 | RPS6KA5 (0.82) | RPS6KA5DYRK1ARPS6KB1ROCK1CDK2 | |
| SCHEMBL4760551 | 0.80 | RPS6KA5 (0.63) | RPS6KA5DYRK1ARPS6KB1ROCK1CDK2 | |
| SCHEMBL8291812 | 0.80 | RPS6KA5 (0.60) | RPS6KA5DYRK1ARPS6KB1ROCK1CDK2 | |
| SCHEMBL5453993 | 0.80 | RPS6KA5 (0.67) | RPS6KA5DYRK1ARPS6KB1ROCK1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1490367-B1 | IMIDAZOPYRIDINE DERIVATIVES AS KINASE INHIBITORS | GLAXO GROUP LTD (GB) | 2008-07-23 | — | — | EP | disclosed |
| EP-1490367-B1 | IMIDAZOPYRIDINE DERIVATIVES AS KINASE INHIBITORS | GLAXO GROUP LTD (GB) | 2008-07-23 | — | — | EP | disclosed |
| US-7348339-B2 | 2-(4-amino-furazan-3-yl)-1-ethyl-N-[(2R)-2-morpholinylmethyl]-1H-imidazo[4,5-c]pyridine-7-carboxamide; Mitogen- and Stress-Activated Protein (MSK) and Rho (guanosine triphosphate) 1 or 2 kinase inhibitor; neurodegenerative diaeases; antiinflammatory, anticarcinogenic, antiviral and antibacterial agent | GLAXO GROUP LIMITED (GB) | 2008-03-25 | — | — | US | disclosed |
| US-7348339-B2 | 2-(4-amino-furazan-3-yl)-1-ethyl-N-[(2R)-2-morpholinylmethyl]-1H-imidazo[4,5-c]pyridine-7-carboxamide; Mitogen- and Stress-Activated Protein (MSK) and Rho (guanosine triphosphate) 1 or 2 kinase inhibitor; neurodegenerative diaeases; antiinflammatory, anticarcinogenic, antiviral and antibacterial agent | GLAXO GROUP LIMITED (GB) | 2008-03-25 | — | — | US | disclosed |
| US-7348339-B2 | 2-(4-amino-furazan-3-yl)-1-ethyl-N-[(2R)-2-morpholinylmethyl]-1H-imidazo[4,5-c]pyridine-7-carboxamide; Mitogen- and Stress-Activated Protein (MSK) and Rho (guanosine triphosphate) 1 or 2 kinase inhibitor; neurodegenerative diaeases; antiinflammatory, anticarcinogenic, antiviral and antibacterial agent | GLAXO GROUP LIMITED (GB) | 2008-03-25 | — | — | US | disclosed |
| US-20050197328-A1 | Imidazopyridine derivatives as kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2005-09-08 | — | — | US | disclosed |
| EP-1490367-A1 | IMIDAZOPYRIDINE DERIVATIVES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003080610-A1 | IMIDAZOPYRIDINE DERIVATIVES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197328-A1 | Imidazopyridine derivatives as kinase inhibitors | NR4A3, XDH, MAPK8 | RPS6KA5 375/4885DYRK1A 358/4885RPS6KB1 668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.